In modern glioma care, the tumor's genetics are as important as its appearance. Molecular testing — analyzing the genes and chromosomes inside the tumor — now defines diagnoses, refines grades, predicts behavior, and matches patients to targeted treatments. Here are the markers you're most likely to hear about.
- IDH mutation. The most important marker in adult diffuse gliomas. IDH-mutant tumors tend to behave more favorably than IDH-wildtype tumors and now define key tumor types. (Covered in depth in its own article.)
- 1p/19q codeletion. The loss of specific pieces of chromosomes 1 and 19. Combined with an IDH mutation, this defines oligodendroglioma and is associated with a better treatment response.
- MGMT promoter methylation. A marker that predicts how well the chemotherapy drug temozolomide is likely to work, especially in glioblastoma. (Also covered in its own article.)
- CDKN2A/B deletion. A change that can push an IDH-mutant astrocytoma to grade 4 even without aggressive appearance.
- H3 K27 alteration. Defines diffuse midline glioma, an aggressive tumor seen mainly in children and young adults.
- BRAF alterations. Important in many pediatric low-grade gliomas and now targetable with specific drugs.
- TERT, EGFR, +7/−10 and others can help define glioblastoma in adults.
How is this tested? After tissue is obtained, the lab may use techniques ranging from immunostaining to DNA sequencing and, at some centers, DNA methylation profiling, which classifies tumors by their overall epigenetic "fingerprint."
The practical message: when you receive a long list of molecular results, you're not looking at noise. Each marker is a clue that helps your team name the tumor precisely, estimate how it will behave, and choose — or rule out — specific treatments. It's reasonable to ask your oncologist to walk you through your tumor's markers and what each one means for your plan.